Order Drugs Now

TEL: 1 866 893 0369
FAX: 1 866 402 4033


Medical News

Subscribe to Newsletter

To get info on the latest products, specials and pharmacy news, please enter your e-mail address:


 

August 19th, 2009
New Anti-T-Cell Globulin Treatment May Minimize Graft-Versus-Host Disease

A recent study proclaims that patients who require a blood stem-cell transplant may be able to lessen the risk of graft-versus-host disease (GVHD - transplanted materials attack the body), thanks to ant-T-cell globulin treatment.

August 19th, 2009
Decade Long Government Led Effort Results in Reduced Heart Attacks

The August 19 issue of the Journal of the American Medical Association details a decade-long government led effort to minimize the death rate of hospitalized heart attack patients as well as upgrade the hospital’s execution of these daily emergencies.

August 19th, 2009
Study Explores New Colon Cancer Treatment Option

A new study believes that drugs that are intended to treat cell surface molecule ERBB3, can provide a more potent way of treating colon cancer. ERBB3 is closely associated to epidermal growth factor receptor (EGFR), drugs used to treat EFGR have proven effective at tackling various cancers, but not colon cancer. Drugs used to treat ERBB3 have proven, however, to be more successful than EGFR inhibitors at targeting colon cancer.

August 19th, 2009
Researchers Claim Avadia Type 2 Diabetes Treatment is Less Safe than Actos

A Canadian research study states that Avandia, used for the treatment of type 2 diabetes, elevates the risk of heart failure and death more so than Actos.

August 19th, 2009
Ancient Chinese Herbal Medicine Shows Promise for Rheumatoid Arthritis

A new study is looking back to ancient Chinese herbal medicine for contemporary treatment options. The Chinese herb in question referred to as “thunder god vine,” has been shown to minimize inflammation for rheumatoid arthritis patients.

August 19th, 2009
FDA Advises of Pure Red Cell Aplasia Found in CellCept Patients

The U.S. FDA and Roche have informed healthcare practitioners that patients being treated with CellCept, have reported cases of Pure Red Cell Aplasia, also known as PRCA.

August 19th, 2009
Gaucher Treatment Drug prGCD Newly Approved

Although, prGCD, a new drug used to treat patients with a unique genetic disorder - Gaucher disease, has not received full market approval, the U.S. FDA has said that physicians may utilize the drug for treatment.

August 17th, 2009
FDA Endorses Multiple Sclerosis Treatment, Extavia

Novartis has recently announced the U.S. FDA approval of their multiple sclerosis treatment drug: Extavia (Interferon beta 1-b). The FDA approved the drug for patients that suffer from a relapse of the auto immune disease, or for those patients whom are newly diagnosed with MS.

August 17th, 2009
DSG’s EDC Enables Human Genome to Achieve Benlysta Drug Objectives

After Benlysta achieved the primary endpoint in Bliss - 52, Human Genome Sciences, is pleased report that the first two pivotal Phase 3 trials involving patients with serologically active systematic lupus erythematous has been completed. The results have began to prove that Benlysta may in fact possess the potential to become the first approved systematic lupus treatment in decades.

August 17th, 2009
Saphris Sublingual Tabs Receives FDA Endorsement

The US FDA has approved Saphris sublingual tablets for the acute therapy of schizophrenic adults, as well as the acute therapy of manic or mixed bipolar I disorder, with or without adult psychotic attributes. Saphris is endorsed for first-line therapy, and is the first prescription drug to receive primary consent for both of these symptoms concurrently.

SEARCH

Search for Medication or Types of Conditions

SHOPPING CART

cart

Items in cart: 0
Total: $0.00

view my cart check out credit cards

Find out how much you can save now!

try
download order form

ALL PRESCRIPTION DRUGS FILLED BY:

Medicine Shoppe Pharmacy
148 #9 31205 Maclure Road
Abbotsford BC, Canada

Ph: 1-866-893-0369
Fax: 1-800-878-7930

Licence J30
Manager: S. Maan

 

TEL: 1 (866) 893-0369
FAX: 1 (800) 878-7930